2) Immunofluorescence staining for Collagen IV and Fibrinogen: Abnormally broad and fragmented BMZ with reduplication 
LICHEN PLANUS
Lichen planus is a common skin disorder that can also involve mucous membranes, scalp, nails and the genitalia. Although its cause is unknown, an autoimmune mechanism is thought to play a major pathophysiological role . There has been no gender or racial predilection associated with lichen planus. The incidence of this disease in dermatology clinics is 1.4%, as compared to 5.0% found in oral medicine clinics . The age of the individuals affected is 30 to 60 years.
CLINICAL FEATURES
The clinical presentation of lichen planus can be characterized by its configuration (linear vs annular), morphology (hypertrophic, follicular, vesicular or bullous) and the site of the lesions. This review will concentrate in the mucous membranes and skin manifestations.
Skin
The cutaneous lesions of lichen planus are typically erythematous to violaceous papules, scaly with a flat topped, polygonal form . The papules tend to involve more commonly the flexural areas of the wrist and forearms. Other skin sites involved include; legs, thighs, lower back, trunk, neck and scalp. The skin lesions in lichen planus tend to be intensely pruritic. However, evidence of skin trauma, secondary infection or bloody crust is infrequent. In 20% of the patients, the lesions can be asymptomatic .
Mucous Membranes: Oral Mucosa
The oral lesions have a radiating velvet, white or gray appearance, most commonly in a reticulated pattern. This represents the "lace-like" network of linear subepithelial fibrosis found in these lesions. The buccal and glossal mucosas are most commonly affected, however, lesions can also be found in the palate and gingiva (erosive gingivitis).
Figure 6: Lichen planus oral mucosal lesion
Pain and burning sensation have been associated with the erosive form of oral lichen planus. Nevertheless, the lesions can also be asymptomatic. In 15% to 30% of the patients with lichen planus, oral lesions can be the sole manifestation of the disease .
Mucous Membranes: Conjunctiva
Involvement of the conjunctiva is rare, however, it has been described since the early 20th century . Most recently, in a study of 584 patients with lichen planus who were evaluated in an oral medicine clinic for extra-oral manifestations, only 1 patient was found to have conjunctival manifestations . Although rare, conjunctival inflammation can be severe and lead to subepithelial fibrosis and scarring . The presence of cicatrizing conjunctivitis in a patient with known history of lichen planus,does not establish the diagnosis of conjunctival lichen planus. Lupus, bullous pemphigoid and other autoimmune disorders have been described to occur in patients with lichen planus . Therefore, a thorough histological analysis, including immunofluorescence staining, most be performed in order to make a definite diagnosis.
IMMUNOPATHOLOGICAL CHARACTERISITICS
Conjunctival lichen planus has been found to have distinct immunopathological characteristics in biopsy specimens . First, no immunoreactants complexes deposition is present in the BMZ of the conjunctiva. This is important in ruling out other immunobullous diseases such as ocular cicatricial pemphigoid. Secondly and most important, thickening and reduplication of the BMZ is shown by staining for Collagen IV and VII, fibrinogen and laminin . 
Prognosis
In most patients lichen planus is benign and usually a self-limited disease. The duration is related to the extension and site of involvement. In general, two third of the patients will have spontaneous resolution in a period of 8 to 12 months.
Skin disease alone= 11 months
Skin and mucous membranes= 17 months
Oral mucosa alone= 4 to 20 years
Recurrences and exacerbations can occur in 18% to 20% of the cases.
TREATMENT
The use of many different drugs has been used in the treatment of cutaneous and oral lichen planus. More recently, the use of Cyclosporine-A mouthwash in patients with oral lichen planus was found to be effective in decreasing the severity of symptoms, erythema, erosion and reticulation of oral lesion . Since the use of topical cyclosporine has also been shown to be safe and useful in the treatment of immune-mediated ocular surface diseases, we decided to use it for the treatment of this patient . This treatment successfully relieved the patient from symptoms and halted disease progression. Moreover, elimination of the treatment resulted in recurrence of the inflammation, and improvement with reinstitution of the medication .
Recommendation: Cyclosporine-A 2% gtt qid TEACHING POINTS Lichen planus can affect the conjunctiva causing inflammation, subepithelial fibrosis and scarring.
The coexistence of cicatricial conjunctivitis in a patient with history of lichen planus, does not establish the diagnosis of conjunctival lichen planus.
Immunopathological analysis of conjunctival tissue is critical in making the diagnosis.
Immunofluorescence staining of the conjunctiva from patients with lichen planus shows: A) No deposition of immunoreactants complexes on the BMZ ; B) Thickening and reduplication of the BMZ, shown with staining against fibrinogen, laminin, collagen IV and VII.
Cyclosporine-A 2% eyedrops can be used for the treatment of conjunctival lichen planus.
